Sodium hydrosulfite contractions of smooth muscle are calcium and myosin phosphorylation independent.
In an effort to further understand the processes underlying hypoxic pulmonary vasoconstriction, we examined the mechanism by which sodium hydrosulfite (Na2S2O4), a potent reducing agent and oxygen scavenger, induces smooth muscle contraction. In rat pulmonary arterial strips, sodium hydrosulfite (10 mM) induced contractions that were 65.9 +/- 12.8% of the response to 60 mM KCl (n = 9 segments). Contractions were not inhibited by nisoldipine (5 microM) or by repeated stimulation with caffeine (10 mM), carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone (10 microM), or cyclopiazonic acid (10 microM), all of which eliminated responses to contractile agonists. Maximum force generation after exposure to sodium hydrosulfite was 0.123 +/- 0.013 mN in the presence of 1.8 mM calcium and 0.127 +/- 0.015 mN in the absence of calcium. Sodium hydrosulfite contractions in pulmonary arterial segments were not due to the generation of H2O2 and occurred in the presence of chelerythrine (10 microM), which blocked phorbol ester contractions, and solution hyperoxygenation. Similar contractile responses were obtained in rat aortic and tracheal smooth muscles. Finally, contractions occurred in the complete absence of an increase in myosin light chain phosphorylation. Therefore sodium hydrosulfite-induced smooth muscle contraction is not specific to pulmonary arterial smooth muscle, is independent of calcium and myosin light chain phosphorylation, and is not mediated by either hypoxia or protein kinase C.
Yu
M F
MF
Department of Animal Biology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, 19104, USA.
Gorenne
I
I
Su
X
X
Moreland
R S
RS
Kotlikoff
M I
MI
D000470:Alkaloids; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000502:physiology; D053119:Benzophenanthridines; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism* / Q000494:pharmacology; D002259:Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone / Q000494:pharmacology; D066298:In Vitro Techniques; D007211:Indoles / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects* / Q000502:physiology; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology*; D009218:Myosins / Q000378:metabolism*; D015737:Nisoldipine / Q000494:pharmacology; D010617:Phenanthridines / Q000494:pharmacology; D015240:Phorbol 12,13-Dibutyrate / Q000494:pharmacology; D010766:Phosphorylation; D011189:Potassium Chloride / Q000494:pharmacology; D011651:Pulmonary Artery / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013447:Sulfites / Q000494:pharmacology*; D014132:Trachea / Q000187:drug effects / Q000502:physiology*
D000470:Alkaloids; D053119:Benzophenanthridines; D007211:Indoles; D010617:Phenanthridines; D013447:Sulfites; D002259:Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; D015240:Phorbol 12,13-Dibutyrate; D002110:Caffeine; D015737:Nisoldipine; D011189:Potassium Chloride; C016299:chelerythrine; D009218:Myosins; C042345:hydrogen sulfite; D002118:Calcium; C000543:cyclopiazonic acid